Health Technology Innovations, Inc.
Portland, Oregon, United States
Dr. King is the Chief Scientific Officer of HTI. He was CEO and co-founder of Virogenomics BioDevelopment, Inc.(VBD) a biotechnology research and development company that collaborated extensively with scientists at Oregon Health and Science University (OHSU) that were developing technology with potential commercial applications. Prior to founding VBD Dr. King was Director of Bioinformatics and later COO and CEO of Virogenomics, Inc. At Virogenomics and VBD Dr. King has had collaborator or PI roles on over $17 M in non-dilutive SBIR and STTR awards for diagnostic and drug development projects. Dr. King was Senior Manager of Lead Validation at Rosetta Inpharmatics (acquired by Merck in 2001) and was Manager of Compound Profiling at Acacia Biosciences. Dr. King received a B.S. degree in engineering physics from the University of Arizona and a Ph.D. degree in biophysics from the University of California, Berkeley. Prior to working in the biotechnology industry, he was an Assistant Research Molecular Biologist at the University of California, San Francisco and a Human Frontier Postdoctoral Fellow at the University of Bern in Switzerland.
Vision Systems for Volume Electron Microscopy
Tuesday, July 30, 2024
11:00 AM - 11:15 AM US EST
